FORMULATION ARTICLES

FORMULATION VIDEOS

It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

Explore how lipid nanoparticles are driving breakthroughs in cell therapy, from mRNA-based immune cell engineering to genome editing for CAR T cells and HSPCs from leading experts.

Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS